×
Incyte Cash on Hand 2010-2024 | INCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Incyte cash on hand for the quarter ending September 30, 2024 was
$1.775B
, a
49.53% decline
year-over-year.
Incyte cash on hand for 2023 was
$3.656B
, a
12.88% increase
from 2022.
Incyte cash on hand for 2022 was
$3.239B
, a
37.93% increase
from 2021.
Incyte cash on hand for 2021 was
$2.348B
, a
30.36% increase
from 2020.
View More
Incyte Cash on Hand 2010-2024 | INCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Incyte cash on hand for 2023 was
$3.656B
, a
12.88% increase
from 2022.
Incyte cash on hand for 2022 was
$3.239B
, a
37.93% increase
from 2021.
Incyte cash on hand for 2021 was
$2.348B
, a
30.36% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$150.5B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$115.4B
Gilead Sciences (GILD)
$109.4B
CSL (CSLLY)
$85.4B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$34.4B
Alnylam Pharmaceuticals (ALNY)
$30.2B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$22.6B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$18.3B
Moderna (MRNA)
$14.3B
Genmab (GMAB)
$13.6B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.8B
Vaxcyte (PCVX)
$10.9B
Bio-Techne Corp (TECH)
$10.5B
Sarepta Therapeutics (SRPT)
$10.2B
Exact Sciences (EXAS)
$10B
Exelixis (EXEL)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
QIAGEN (QGEN)
$9.3B
Intra-Cellular Therapies (ITCI)
$8.8B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$7.5B
Repligen (RGEN)
$7.2B
Legend Biotech (LEGN)
$7B